Acute Kidney Injury Due to Nephrolithiasis in Autosomal Dominant Polycystic Kidney Disease Treated With Tolvaptan: A Case Report

被引:0
|
作者
Shima, Hisato [1 ,2 ]
Nishitani, Masaaki [3 ]
Izaki, Hirofumi [4 ]
Minakuchi, Jun [1 ]
机构
[1] Kawashima Hosp, Kidney Dis, Tokushima, Japan
[2] Kamei Hosp, Nephrol & Hypertens, Tokushima, Japan
[3] Kawashima Hosp, Urol, Tokushima, Japan
[4] Tokushima Prefectural Cent Hosp, Urol, Tokushima, Japan
关键词
tolvaptan; nephrolithiasis; transurethral lithotripsy; acute kidney injury; autosomal dominant polycystic kidney disease; CALCULI;
D O I
10.7759/cureus.62597
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 61 -year -old asymptomatic female with autosomal dominant polycystic kidney disease (ADPKD) on tolvaptan therapy was hospitalized for acute kidney injury (AKI). Nephrolithiasis had already been diagnosed; however, the patient had not undergone any interventions. She also presented with hyponatremia possibly caused by overhydration. Because the estimated glomerular filtration rate (eGFR) decline was significantly higher than the predicted rate, we considered a possible case of postrenal AKI and examined computed tomography (CT), which revealed left hydronephrosis with a 9.4 -mm ureteric stone at the level of L3/L4. We restricted fluid intake, which resulted in an increase in sodium levels. She was treated with transurethral lithotripsy (TUL) twice, which successfully improved her kidney function. Although the serum sodium levels increase because of aquaresis in almost all patients treated with tolvaptan, our case was unique in that the patient presented with hyponatremia. We should pay more attention to the periodical follow-up of nephrolithiasis in addition to the increase in total kidney volume and decide the appropriate time to treat nephrolithiasis depending on the case. We should also keep in mind that ADPKD patients have a high frequency of nephrolithiasis and, even if asymptomatic, investigate urinary tract obstruction and hydronephrosis in case of AKI.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] Infertility treatment in autosomal dominant polycystic kidney disease (ADPKD) -: a case report
    Orhan, I
    Onur, R
    Ergin, E
    Köksal, IT
    Kadioglu, A
    ANDROLOGIA, 2000, 32 (02) : 91 - 93
  • [42] Amyloidosis in a patient with autosomal dominant polycystic kidney disease and tuberculosis: a case report
    Sar, Fuat
    Taylan, Ismail
    Kutlu, Cigdem
    Caymaz, Muazzez Sezer
    Tatli, Emel
    Kazancioglu, Rumeyza
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2007, 39 (02) : 655 - 659
  • [43] Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Raina, Rupesh
    Houry, Ahmad
    Rath, Pratik
    Mangat, Guneive
    Pandher, Davinder
    Islam, Muhammad
    Khattab, Ala'a Grace
    Kalout, Joseph K.
    Bagga, Sumedha
    DRUG HEALTHCARE AND PATIENT SAFETY, 2022, 14 : 147 - 159
  • [44] Long-term effectiveness and safety of tolvaptan in autosomal dominant polycystic kidney disease
    Cantarelli, Lorenzo
    Valencia, Marta Gutierrez
    Alegria, Leire Leache
    Fernandez, Luis Carlos Sainz
    Lopez, Juan Erviti
    Nicolas, Fernando Gutierrez
    Casariego, Gloria Julia Nazco
    MEDICINA CLINICA, 2024, 163 (01): : 1 - 7
  • [45] Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment
    Rodriguez-Espinosa, Diana
    Jesus Broseta, Jose
    Bastida, Carla
    Isabel Alvarez-Mora, Maria
    Nicolau, Carlos
    Alvarez, Cristina
    Agraz-Pamplona, Irene
    Sanchez-Baya, Maya
    Furlano, Monica
    Ruiz, Cesar
    Quintana, Luis F.
    Pineiro, Gaston J.
    Poch, Esteban
    Torra-Balcells, Roser
    Blasco, Miquel
    NEPHRON, 2023, 147 (3-4) : 152 - 157
  • [46] Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease
    Grampsas, SA
    Chandhoke, PS
    Fan, J
    Glass, MA
    Townsend, R
    Johnson, AM
    Gabow, P
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 36 (01) : 53 - 57
  • [47] Comparison of Different Selection Strategies for Tolvaptan Eligibility among Autosomal Dominant Polycystic Kidney Disease Patients
    Wulfmeyer, Vera C.
    Auber, Bernd
    Haller, Hermann
    Schmitt, Roland
    AMERICAN JOURNAL OF NEPHROLOGY, 2019, 50 (04) : 281 - 290
  • [48] Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan
    Higashihara, Eiji
    Horie, Shigeo
    Muto, Satoru
    Kawano, Haruna
    Tambo, Mitsuhiro
    Yamaguchi, Tsuyoshi
    Taguchi, Satoru
    Kaname, Shinya
    Yokoyama, Kenich
    Yoshioka, Tatsuya
    Furukawa, Toshihito
    Fukuhara, Hiroshi
    AMERICAN JOURNAL OF NEPHROLOGY, 2020, 51 (11) : 881 - 890
  • [49] Con: Tolvaptan for autosomal dominant polycystic kidney disease-do we know all the answers?
    Gross, Peter
    Schirutschke, Holger
    Paliege, Alexander
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 (01) : 35 - 37
  • [50] Recognizing and treating autosomal dominant polycystic kidney disease
    Uko, Chigozie G.
    NURSE PRACTITIONER, 2020, 45 (11) : 41 - 47